To appraise the clinical and cost effectiveness of:Nivolumab in combination with rucaparib, docetaxel or enzalutamide within its marketing authorisation for prostate cancer
Following on from information provided to NICE by the company in February 2020, the appraisal of Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1621

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
22 November 2022 Discontinued. Following on from information provided to NICE by the company in February 2020, the appraisal of Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
12 February 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621] The company have advised that they will not be pursuing a Marketing Authorisation Application for nivolumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if the situation changes.
05 September 2019 In progress. Referred 29 April 2019

For further information on our processes and methods, please see our CHTE processes and methods manual